Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Accumulated Expenses: 2019-2024

Historic Accumulated Expenses for Fulcrum Therapeutics (FULC) over the last 6 years, with Dec 2024 value amounting to $7.7 million.

  • Fulcrum Therapeutics' Accumulated Expenses fell 22.87% to $6.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.4 million, marking a year-over-year decrease of 22.87%. This contributed to the annual value of $7.7 million for FY2024, which is 11.83% down from last year.
  • As of FY2024, Fulcrum Therapeutics' Accumulated Expenses stood at $7.7 million, which was down 11.83% from $8.7 million recorded in FY2023.
  • Over the past 5 years, Fulcrum Therapeutics' Accumulated Expenses peaked at $9.6 million during FY2022, and registered a low of $7.3 million during FY2020.
  • Over the past 3 years, Fulcrum Therapeutics' median Accumulated Expenses value was $8.7 million (recorded in 2023), while the average stood at $8.7 million.
  • Its Accumulated Expenses has fluctuated over the past 5 years, first spiked by 32.22% in 2020, then dropped by 11.83% in 2024.
  • Over the past 5 years, Fulcrum Therapeutics' Accumulated Expenses (Yearly) stood at $7.3 million in 2020, then grew by 27.03% to $9.2 million in 2021, then rose by 3.47% to $9.6 million in 2022, then declined by 8.64% to $8.7 million in 2023, then dropped by 11.83% to $7.7 million in 2024.